Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Biofrontera Inc. Common Stock

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Biofrontera Inc.

#NowHiring: The #Biofrontera team is searching for a new Jr. Territory Manager in Chicago, IL! 

If you're ready to make a difference in #dermatology, visit ⤵️

#SalesPosition #ComeGrowWithUs

📢 We're hiring a Territory Manager in Chicago, IL! 

Ready to help the #Biofrontera team spread the word about our innovative dermatological treatments? Apply today ⤵️ 

#ComeGrowWithUs

Today we shared #Bioftonera's #Q3 financial results for 2023. To learn more, visit the link below: ⤵️

#BiofronteraNews #Dermatology

Meet #Biofrontera Quality Assurance Director, Darrell Lowman! Darrell has been instrumental in our success as a company and is a natural-born leader. We are lucky to have him!

To learn more about our team, visit: https://loom.ly/xeWeBoE

#GetToKnowUs #PDT #EmployeeSpotlight #Dermatology

Are you a #Dermatology NP or PA and looking to transition to industry? Are you located in the Northeast? Do you want to join a dynamic team and fuel your career growth? If so, please check out #Biofrontera's open position for a Medical Science Liaison. ⤵️

#ComeGrowWithUs #NowHiring

#Biofrontera was happy to support and take part in the YoungMD Connect Networking Event this weekend in Chicago, connecting with some of the rising stars of #dermatology!

Thank you to Sally Cioci Fischer and the Practical Dermatology team for organizing such a great event!

Mouna Mikati, Ph.D. Kristina Malkhasova, Pharm. D. 

#BiofronteraontheMove

Join the #Biofrontera team as a Senior Financial Analyst at our headquarters in Woburn, MA! 

Discover how you can help to make a difference in #dermatology. Apply now ⤵️

We had a great time at the Ohio Dermatological Annual Meeting this past weekend! It's always a pleasure running into Dr. Scott Drew and Delaney Drew.

Thank you to our own Amy Ward Cline for holding down the booth and sharing the latest about 

#Biofrontera! #BiofronteraOnTheMove #Dermatology

We have news! To learn more about the latest #Biofrontera updates, visit: https://loom.ly/ZfcmM4o

#BiofronteraNews #Dermatology

Happy Halloween from all of us at #Biofrontera! Our latest training class joined some of our HQ team for a spooktacular time at our annual Halloween celebration. 

We celebrated with a costume contest as well a painting contest and DIY cookie decorating!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-10.98M -	-10.99M 0.05%	-37.71M 243.25%	-640K 98.30%	-20.13M 3,045.47%
depreciation and amortization	667K -	562K 15.74%	540K 3.91%	1.17M 117.04%	1.06M 9.22%
deferred income tax			12.88M -		-1.13M -
stock based compensation			129K -	1.85M 1,335.66%	1.04M 43.57%
change in working capital	-23.94M -	-2.83M 88.19%	-1.50M 46.76%	2.79M 285.25%	-4.39M 257.60%
accounts receivables	-757K -	1.17M 254.43%	-612K 152.35%	-70K 88.56%	4.93M 7,148.57%
inventory	-3.54M -	2.98M 184.15%	2.59M 12.96%	-2.81M 208.41%	-3.75M 33.45%
accounts payables	1.44M -	-6.65M 562.66%	-773K 88.38%	912K 217.98%	6.42M 603.40%
other working capital	-21.08M -	-321K 98.48%	-2.71M 744.86%	4.76M 275.37%	-11.99M 352.17%
other non cash items	-3.42M -	883K 125.80%	-1.04M 218.23%	-21.37M 1,947.03%	-1.35M 93.68%
net cash provided by operating activities	-37.68M -	-12.37M 67.17%	-26.71M 115.98%	-16.20M 39.36%	-24.89M 53.68%
investments in property plant and equipment	-538K -		-11K -	-38K 245.45%	-5K 86.84%
acquisitions net	25.93M -
purchases of investments				-5.12M -
sales maturities of investments					624K -
other investing activites
net cash used for investing activites	25.39M -		-11K -	-5.16M 46,772.73%	619K 112.01%
debt repayment	-13.50M -	-8.79M 34.86%			-3.90M -
common stock issued			29.94M -	9.39M 68.63%	4.51M 52.01%
common stock repurchased
dividends paid
other financing activites	29.90M -	21.99M 26.46%	13.25M 39.73%	4.63M 65.06%	7.81M 68.64%
net cash used provided by financing activities	16.40M -	13.19M 19.55%	43.19M 227.35%	14.02M 67.54%	8.41M 40.01%
effect of forex changes on cash
net change in cash	4.12M -	825K 79.97%	16.46M 1,895.76%	-7.33M 144.54%	-15.87M 116.32%
cash at beginning of period	3.33M -	7.45M 123.52%	8.28M 11.07%	24.74M 198.92%	17.21M 30.45%
cash at end of period	7.45M -	8.28M 11.07%	24.74M 198.92%	17.41M 29.64%	1.34M 92.29%
operating cash flow	-37.68M -	-12.37M 67.17%	-26.71M 115.98%	-16.20M 39.36%	-24.89M 53.68%
capital expenditure	-538K -		-11K -	-38K 245.45%	-5K 86.84%
free cash flow	-38.22M -	-12.37M 67.63%	-26.73M 116.07%	-16.24M 39.25%	-24.90M 53.35%

COM:BIOFRONTERA-US

Biofrontera Inc.

Last Close

0.76

22/11 21:00

Market Cap

6.74M

Beta: -

Volume Today

7.71M

Avg: -

Preview